# Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

> **NCT00113269** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 501 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** basiliximab
- **DRUG:** rabbit anti-thymocyte globulin
- **DRUG:** tacrolimus
- **DRUG:** alemtuzumab
- **DRUG:** mycophenolate mofetil
- **DRUG:** steroids

## Key facts

- **NCT ID:** NCT00113269
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 501 (ACTUAL)
- **Last updated:** 2011-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00113269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00113269, "Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00113269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*